FIELD: medicine.
SUBSTANCE: this invention relates to agonistic anti-MET antibodies and their use in the treatment of diseases. These antibodies bind with high affinity to the human and mouse hepatocyte growth factor (hereinafter – HGF) receptor, also known as MET, and are MET agonists in both humans and mice, leading to molecular and cellular effects similar to effects of HGF binding, which allows experiments conducted on preclinical models to be made prognostic in a human situation.
EFFECT: obtaining anti-MET antibodies for the treatment of diseases.
14 cl, 31 dwg, 24 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| LIGAND-BINDING MOLECULE WITH REGULATED LIGAND-BINDING ACTIVITY | 2017 |
|
RU2803067C2 |
| IMMUNOACTIVATING ANTIGEN-BINDING MOLECULE | 2015 |
|
RU2722788C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC-REGION VARIANTS, AND THEIR APPLICATION METHODS | 2016 |
|
RU2789884C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
| COMBINATION OF ANTIBODY AGAINST HGFR AND HEGFR FOR TREATMENT OF TUMOR AND/OR METASTASIS | 2019 |
|
RU2788606C2 |
| MONOCLONAL BINDING AGENTS, THEIR DRUG CONJUGATES AND THEIR APPLICATIONS | 2017 |
|
RU2744914C2 |
| ANTIBODIES TO MYOSTATIN, POLYPEPTIDES CONTAINING FC REGION VARIANTS AND METHODS OF THEIR USE | 2015 |
|
RU2799522C2 |
